MedAxiom Announces Industry Partnership with BioTel Heart

BioTel Heart enables healthcare providers to remotely monitor and diagnose patients more efficiently, accurately and cost-effectively.

Partner News | Published: Wednesday, October 23, 2019

MedAxiom, the nation’s leading cardiovascular healthcare membership organization and performance community, is excited to announce its industry partnership with BioTel Heart, a division of BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce the cost of care.

“BioTel Heart is a fast growing company that has pioneered arrhythmia monitoring to help diagnose cardiac patients,” said Joe Sasson PhD, EVP of MedAxiom Ventures. “We are excited to welcome them as a MedAxiom Industry Partner and bring their offerings of remote arrhythmia monitoring via Holters, Event Monitors, and MCOT™ to our membership community. We are confident that BioTel Heart’s expertise around both product and deployment strategies will help accelerate the evolution and success of our member network in this critical and growing domain.”

BioTel Heart processes over four billion heartbeats per day and monitors over one million patients each year, working with over 30,000 prescribing physicians and most of the top hospitals in the nation. It is the pioneer in remote patient monitoring, revolutionizing healthcare with its suite of cardiac monitoring devices, including its FDA-cleared ePatch™ and Mobile Cardiac Outpatient Telemetry (MCOT™) monitors. 

“Our passion for connecting people to solutions that save lives drives our innovation and partnerships,” said Andy Broadway, President of BioTel Heart. “Our best-in-class technology and services enable healthcare providers to monitor and diagnose patients more effectively, and we are constantly looking for new and different ways to make a difference for our patients, customers and communities. We are proud to partner with MedAxiom and delighted to work with an organization that shares our passion.”

BioTel Heart was the first company to provide heartbeat-to-heartbeat ECG monitoring service, analysis and response for patients at home or away, every hour of every day. BioTel Heart’s MCOT is the most accurate and most studied arrhythmia monitoring detection system, providing near real-time arrhythmia detection with rate, rhythm, AF with p-wave analysis and a QRS morphology algorithm. MCOT is the only monitoring device proven to detect atrial fibrillation with 100 percent sensitivity and 100 percent positive predicitivity in the detection of ≥30-second AF episodes, and has been validated by clinical evidence from 41 studies, abstracts and articles. Certified cardiac technicians review findings and comprehensive clinical reports for MCOT in a HIPAA-protected, online system and are available every hour of every day.  Additionally, through BioTelemetry’s recent acquisition of Geneva Health Solutions, it focuses on workflow solutions, including EMR implementations with all major EMR systems, helping cardiology providers manage the data deluge from cardiac devices, including implantable loop recorders (ILRs).

MedAxiom members will have an opportunity to learn more about BioTel Heart at the CV Transforum Fall’19 conference, October 24-26, in Dana Point, CA.


About MedAxiom

MedAxiom, an American College of Cardiology Company, is the cardiovascular community’s largest membership and resources network and the leading cardiovascular-specific consulting team in the U.S. MedAxiom is transforming cardiovascular care by combining the knowledge and power of more than 400 cardiovascular organization members and thousands of providers, administrators and clinicians. Through the delivery of proprietary tools, smart data and proven strategies, MedAxiom helps cardiovascular organizations achieve the Quadruple Aim of better outcomes, lower costs, improved patient experience and improved clinician experience.

For additional information, visit

About BioTel Heart

BioTel Heart®, a division and tradename of BioTelemetry, Inc., is a leading provider of remote patient monitoring, processing over four billion heartbeats per day and monitoring over one million patients each year. It is the pioneer in remote patient monitoring, revolutionizing healthcare with its suite of cardiac monitoring devices including its FDA-cleared ePatch™ and Mobile Cardiac Outpatient Telemetry (MCOT™) monitors. More information can be found at

BioTelemetry is advancing health by providing technology and services that enable healthcare providers to monitor and diagnose patients and clinical research subjects in a more efficient, accurate and cost-effective manner. It is one of the largest and fastest growing connected health companies and was recently ranked 31st on Fortune Magazine’s 100 Fastest-Growing companies list for 2019. More information can be found at

This site uses cookies to improve your experience.

By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.